Application and future scope in drug-delivery

1. DNA Origami
Application and future scope in drug-delivery
Presentation By
NURUDDIN BAHAR-2373100
DANI ASSI-2145625
SERENE PAULY-2423716
SRI VIDHYA LAKSHMI-2414974
NASSER ALSULAIMAN-2339501

2. Preparing DNA
Origami in Lab
Progress in DNA
Origami
Architecture of
DNA Origami
c Han, D., Pal, S., Nangreave, J., Deng, Z., Liu,
Y., & Yan, H. (2011). DNA origami
with complex curvatures in
three-dimensional space. Science,
332(6027), 342–346.
Zhang, F., Jiang, S., Wu, S., Li, Y., Mao, C.,
Liu, Y., & Yan, H. (2015). Complex
wireframe DNA origami nanostructures
with multi-arm junction vertices. Nature
Nanotechnology, 10(9), 779–784.

4. Rothemund, P. W. K. (2006). Folding DNA to
create nanoscale shapes and patterns.
Nature, 440(7082), 297–302.

6. STEPS INVOLVED IN
CANDANO

9. Introduction to Drug Delivery in Cancer Therapy
• A new era of Targeted drug delivery and precision medicine using nanotechnology in Cancer therapy
• DNA structures are modified with functional groups to act as a DNA carriers, which can directly deliver
the drug into specified target cells.
• This application came into existence with the appearance of scaffolded DNA origami method.
• The conventional method has many drawbacks like low solubility, low stability, and cytotoxicity. Thus,
leads to inadequate efficiency of cancer therapy.
• This technique uses DNA nanostructures for delivering the drug directly into the cancer cells and
reduces severe side effects.

10. Nanoparticle Drug Delivery in Cancer Therapy
DOXORUBUCIN [DXO]
• Doxorubicin is a type of chemotherapy drug called an anthracycline.
• It slows or stops the growth of cancer cells by blocking an enzyme called topo isomerase.
• DOX can cause deaths of healthy cells too.
• Commonly used doxorubicin-containing regimens are AC,TAC, ABVD, BEACOPP, CHOP and FAC.
CA 15-3 Breast cancer CA 27-29 Breast cancer Doxorubicin [DOX]

11. Delivery of DOX using Oncomarker Signature
DNA Origami Shell DOX Nanoparticle starts from Blood stream
DOX getting released inside the cancer cells

12. Main points to be discussed -
● How does Doxorubicin intercalate with DNA origami
● The procedure for building a drug carrier using DNA origami.
DNA Origami : Doxorubicin drug carrier.

13. Functional part of the structure
● Amino acid - not interacting with
the phosphates but is sitting in the
minor groove.
● b, c, and d rings constitute an
intercalative region.
● A ring interact through hydrogen
bonding with the double-helix.
● DOX is intercalated in the GC
sequences
Pérez-Arnaiz, C., Busto, N., Leal, J.M. and García, B., 2014. New insights into the mechanism of the DNA/doxorubicin interaction. The Journal of Physical
Chemistry B, 118(5), pp.1288-1295.

14. Figure 2. (a) Doxorubicin intercalated with DNA origami delivery system assembly. The M13mp18 scaffold strand (blue) is folded
into the triangle and tube structures through the hybridization of staple strands. Watson−Crick base pairs in the double helices
serve as docking sites for doxorubicin intercalation. (b) drug loading efficiencies: Efficiency of doxorubicin incorporation into
triangle- and tube-shaped DNA origami carriers and double-strand M13 DNA.
Jiang, Q., Song, C., Nangreave, J., Liu, X., Lin, L., Qiu, D., Wang, Z.G., Zou, G., Liang, X., Yan, H. and Ding, B., 2012. DNA origami as a carrier for
circumvention of drug resistance. Journal of the American Chemical Society, 134(32), pp.13396-13403.

15. The advantages
❖ Stable.
❖ Create complex shape.
❖ Very precise.
❖ Racognies by the bod.
Limitations
❖ Expensive.
❖ Sometimes can be killed by antibody.

16. SUMMARY

17. References
● Slide no. 7: ROTHEMUND, Paul WK. Folding DNA to create nanoscale shapes and patterns. Nature, 2006, 440.7082: 297.
● Slide no 10: Zhang, Q., Jiang, Q., Li, N., Dai, L., Liu, Q., Song, L., Wang, J., Li, Y., Tian, J., Ding, B. and Du, Y., 2014. DNA origami as an in
vivo drug delivery vehicle for cancer therapy. ACS nano, 8(7), pp.6633-6643.
● Slide no 11: Tasciotti, E., 2018. Smart cancer therapy with DNA origami. Nature biotechnology, 36(3), p.234.
● Slide no. 13: Pérez-Arnaiz, C., Busto, N., Leal, J.M. and García, B., 2014. New insights into the mechanism of the DNA/doxorubicin
interaction. The Journal of Physical Chemistry B, 118(5), pp.1288-1295. ; Aubel-Sadron, G. and Londos-Gagliardi, D., 1984. Daunorubicin
and doxorubicin, anthracycline antibiotics, a physicochemical and biological review. Biochimie, 66(5), pp.333-352.
● Slide no 14 - Jiang, Q., Song, C., Nangreave, J., Liu, X., Lin, L., Qiu, D., Wang, Z.G., Zou, G., Liang, X., Yan, H. and Ding, B., 2012. DNA
origami as a carrier for circumvention of drug resistance. Journal of the American Chemical Society, 134(32), pp.13396-13403.